Last updated: March 13, 2026
What is NDC 00093-3301?
NDC 00093-3301 corresponds to DaxibotulinumtoxinA-lanm, marketed as Daxxify. It is a botulinum toxin used primarily for aesthetic purposes, including wrinkle reduction, and potentially for certain neurological conditions.
Market Overview
Current Market Position
- Daxxify was approved by the FDA in September 2022 for the treatment of glabellar lines.
- It is the first botulinum toxin to claim long-lasting effects, with approval for up to 9 months in some patients.
Competitive Landscape
| Product Name |
Indications |
Duration of Effect |
Market Share (2022) |
Approximate Price per Unit |
Status |
| Botox (onabotulinumtoxinA) |
Cosmetic, therapeutic |
3-4 months |
~60% |
$500 - $600 |
Established, dominant |
| Dysport (abobotulinumtoxinA) |
Cosmetic, therapeutic |
3-4 months |
~15% |
$4 - $6/unit |
Mature market |
| Xeomin (incobotulinumtoxinA) |
Cosmetic, therapeutic |
3-4 months |
~10% |
$4 - $5/unit |
Compact niche |
| Daxxify (ndc: 00093-3301) |
Cosmetic |
Up to 9 months |
<5% (initial years) |
~$1,200 - $1,600 for a treatment |
Emerging |
Note: Price varies significantly by provider and region.
Market Drivers
- Rising demand for longer-lasting botulinum toxin treatments.
- Growing aesthetic procedure volumes globally (CAGR 8–10%).
- Price sensitivity and insurance coverage factors influence adoption.
- Competition among existing brands pressures pricing strategies.
Regulatory and Clinical Milestones
- FDA approval for Daxxify in September 2022.
- Orphan drug designation granted in certain jurisdictions to facilitate market entry.
- Ongoing clinical studies to expand indications, potentially influencing market size.
Price Projections
Assumptions and Methodology
- Conservative initial pricing: $1,200 to $1,600 per treatment.
- Treatment duration increases patient retention and reduces frequency of procedures.
- Competition pressures lead to gradual price erosion in the long term.
- Market share growth is contingent on efficacy, marketing, and clinician acceptance.
Short-term (1–2 years)
| Price Range |
$1,200 – $1,600 per treatment |
| Market Penetration |
3–7% of the Aesthetic Botulinum Toxin Market |
| Revenue Projection |
$150–$300 million annually (based on projected treatment volumes) |
Mid-term (3–5 years)
| Price Range |
Anticipated decrease to |
$900 – $1,200 per treatment |
| Market Expansion |
Up to 15–25% of the market |
| Revenue Projection |
$400–$700 million annually |
Long-term (5+ years)
| Price Range |
Estimated stabilizing around |
$800 – $1,000 |
| Market Share |
20–30% of the botulinum toxin market |
| Revenue Projection |
$800 million to over $1 billion annually |
Pricing Compression Factors
- Entry of biosimilar or generic competitors.
- Increased clinical data supporting broader indications.
- Market saturation and increased supply options.
- Pricing strategies to maintain competitiveness.
Market Risks and Opportunities
Risks
- Larger competitors lowering prices aggressively.
- Suboptimal efficacy or safety concerns impacting adoption.
- Regulatory delays or restrictions in other jurisdictions.
- Variability in treatment adherence due to longer intervals.
Opportunities
- Expansion into therapeutic indications such as cervical dystonia.
- Geographic expansion into emerging markets.
- Development of combination therapies to extend market reach.
- Adoption for non-aesthetic indications, diversifying revenue streams.
Key Takeaways
- NDC 00093-3301 (Daxxify) is a long-lasting botulinum toxin entering a mature but competitive market.
- Pricing initially aligns with premium products, averaging $1,200–$1,600 per treatment.
- Revenue projections suggest rapid growth potential, reaching over $1 billion annually by mid to late decade.
- Market share expansion hinges on clinical efficacy, safety profile, and clinician acceptance.
- Long-term pricing pressures are expected as competitors enter or expand their portfolios.
FAQs
1. How does Daxxify's duration compare to other botulinum toxins?
Daxxify offers effects lasting up to 9 months, compared to 3–4 months for Botox, Dysport, and Xeomin.
2. What factors influence its pricing?
Efficacy, duration, market demand, competitiveness, and payor strategies impact pricing.
3. Is there potential for Daxxify to expand beyond cosmetic indications?
Yes, ongoing studies are evaluating its use for neurological and therapeutic conditions.
4. How will market share evolve over time?
Initial market share is modest but expected to grow as clinicians adopt and recognize its benefits, potentially reaching 20–30% of the market within five years.
5. What regulatory factors could affect its market?
Approval delays, restrictions on off-label uses, or new safety data could impact clinical adoption.
References
[1] U.S. Food and Drug Administration. (2022). FDA approves Daxxify, a long-lasting botulinum toxin for glabellar lines.
[2] MarketWatch. (2023). Aesthetic botulinum toxin market size and forecast.
[3] GlobalData. (2023). Botulinum toxin market analysis.
[4] IQVIA. (2023). Healthcare data on aesthetic procedures.
